The cytotoxic efficacy of modified NKG2D-CAR-NK cells against various types of malignancies, including hematological diseases [61] and solid cancers such as lung [62] and colorectal cancer [63], has been confirmed. This evidence concerns the gene KLRK1 and hematologic disorder.